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Pluronic nanoparticles (NPs) were prepared by means of a temperature-induced
phase transition in the mixture composed of Pluronic F-68 and liquid Tween 80/soybean
oil containing model drugs such as orlistat, caffeine, and ibuprofen sodium salt. Liquid
soybean oil/Tween 80 was used as a solubilizer for model drugs, and Pluronic F-68 was
the polymer that stabilizes liquid soybean oil/Tween 80 containing model drugs.
Field-emission scanning electron microscopy and particle size analyzer were used
to observe the morphology and size distribution of the prepared NPs. X-ray diffracto-
meter was used to understand relationship between the crystalline state of the model drug
and its solubility in the aqueous media. To observe the feasibility of Pluronic NPs as a
drug delivery system, the release pattern of model drugs was observed.
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Introduction
Practically insoluble drugs in the aqueous me-
dia still remain as a main issue in the pharmaceuti-
cal area and various methods such as solid disper-
sion, granulation and hot melt extrusion have been
developed to improve the solubility1–3. Recently,
temperature-induced phase transition in the melt
state polymer/drug mixtures has been utilized to
improve the solubility of hydrophobic anticancer
drugs4–5.
Pluronic-based nanoparticles (NPs) were
formed by temperature-induced phase transition in
the melt state of Pluronic/poly ethylene ox-
ide/paclitaxel (PTX) mixture.4 Liquid PEG (molec-
ular weight: 400) was used as a solubilizer of PTX
and the polymer that encapsulates the PTX was
composed of Pluronics F-68. At the phase transition
temperature (120°C for 90 minutes), the polymer
mixture was changed to the liquid phase, and stir-
ring the liquid polymer mixture formed emulsions
composed of PEG containing PTX and liquidized
Pluronic F-68. By cooling to 0°C, PEG containing
PTX was encapsulated by Pluronic F-68 on the
nanometer scale to form Pluronic NPs with
core/shell structure, which was revealed by
cry-transmittance electron microscopy. If the same
process was applied to docetaxel, which was hydro-
phobic anticancer drugs belonging to the second
generation of the taxoid family, the significant oxi-
dation of DTX was observed during the formation
of DTX-loaded Pluronic NPs5. Therefore, a strategy
to produce NPs at a relatively low transition tem-
perature is necessary. Later, an improvement was
made using liquid Tween 80/soybean oil as a
solubilizer for DTX and the new type of DTX for-
mulation was prepared in the aqueous media. The
melting transition was performed at a relatively low
transition temperature (60°C) to avoid the degrada-
tion of the drug or the polymer using liquid Tween
80/soybean oil6.
In this study, Pluronic NPs with Tween80/soy-
bean oil core containing drug were prepared for the
sustained drug delivery system by means of temper-
ature-induced phase transition (see Figure 1).
Model drugs used were orlistat, caffeine and ibu-
profen sodium salt, which were selected with the
variation of solubility. Orlistat is known as tetra-
hydrolipstatin and is a drug designed to treat obe-
sity. The first function of orlistat is blocking the
absorption of fats from the human diet, thereby re-
ducing caloric intake7. Ibuprofen is a non-steroidal
anti-inflammatory drug (NSAID) and belongs to
the group of 2-arylpropionic acids. Ibuprofen
sodium salt is used for the treatment of inflamma-
tory conditions such as rheumatoid arthritis.
Furthermore, it is used for treating mild and moder-
ate pain, dysmenorrhea, headache and fever8. Caf-
feine, which belongs to an alkaloid of the
methylxanthine family, is a naturally occurring sub-
stance found in the leaves, seeds or fruits of over 63
plants species worldwide. Caffeine is an ingredient
in various over-the-counter drugs (OTCs) including
headache, cold, allergy, pain relief and alerting
drugs9–10.
The stability of Pluronic NPs was monitored
by observing the change of size distribution of NPs
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in the aqueous media. X-ray diffractometer was
used to examine the crystalline structure of model
drug, which was closely related to the dissolution
behavior and release pattern of model drug. The re-
lease pattern of model drugs was measured and ex-
plained in terms of the size of NPs and the solubil-
ity of model drugs.
Materials and methods
Materials
Pluronic F-68, poly(ethylene oxide)-poly(pro-
pylene oxide)-poly(ethylene oxide) triblock copoly-
mer (Mw=8350; (EO)79(PO)28(EO)79) was obtained
from BASF Corp., Korea, and was used as re-
ceived. Orlistat, soybean oil, Tween 80, caffeine
and ibuprofen (sodium salt) were purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA).
Preparation of Pluronic NPs
Pluronic NPs were prepared by temperature-in-
duced phase transition. 300 mg of liquid Tween
80/soybean oil and 20 mg of drug (loading amount:
3.2 wt%) were mixed to form a drug-loaded lipid
phase, which was subsequently mixed with
weighed amount of Pluronic F-68. As the tempera-
ture was increased to 75°C, the mixture melted into
a liquid phase. After the equilibrium was main-
tained at 75°C for 15 minutes with stirring, the liq-
uid mixture was then cooled to 0°C for 10 minutes
to induce a phase transition.
Particle size and morphology of Pluronic NPs
The average diameter and size distribution of
NPs (1 mg/ml of NPs dispersed in phosphate buf-
fered saline (PBS, pH 7.4)) were measured via
dynamic light scattering (Zeta Sizer Nano Series) at
632.8 nm and 25°C. Field emission-scanning elec-
tron microscopy (FE-SEM) measurements were
performed to observe the morphology of Pluronic
NPs. To prepare a sample for FE-SEM, 0.1 wt% of
aqueous solution of the Pluronic NPs was prepared
in distilled-deionized water. Each solution was
dropped on a carbon mount and then dried at 25°C
in a vacuum oven for 24 h. FE-SEM measurement
was performed on a JSM-6700F operating at 5 kV.
Differential scanning calorimetry (DSC)
measurements.
Thermal analysis was conducted using a TA
Q2000 (TA Instruments, New Castle, DE, USA).
Nitrogen was used as purge gas at a flow rate of
50 mL/min for the DSC cell. The temperature scale
and cell constants were calibrated by measuring the
onset temperature and the enthalpic response of an
Indium standard. The aluminum pans were hermeti-
cally sealed and the samples were heated from 0°C
to 200°C with the heating rate of 10°C/min. Data
was acquired and analyzed using Universal Analy-
sis 2000 software (TA Instruments, New Castle,
DE, USA).
X-Ray diffraction analysis
The crystalline characteristic of Pluronic NPs
was examined using a Bruker X–ray diffractometer
D8 Advance with Davinci (Bruker AXS GmbH,
Germany) equipped with Ni-filtered Cu K radia-
tion ( = 1.54056 Å) and a LynxEye detector. The
samples were placed in a quartz sample holder and
scanned from 4 to 40° (2 value) at a scanning rate
of 0.2 sec/step.
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F i g . 1 – Formation of Pluronic nanoparticles by tempera-
ture-induced phase transition
In vitro drug release characteristics
from the Pluronic NPs
To measure the release pattern of model drugs
from the NPs, 10 mg of NPs was dispersed in 10
mL of PBS and put into a dialysis bag (MWCO:
500,000, Spectrum®, Rancho Dominquez, CA),
which was immersed in 20 mL of PBS. The experi-
mental setup was placed in a shaking water bath
maintained at 37°C and shaken horizontally at
100 rpm. At predetermined time intervals, 2 mL of
aliquots of release medium (PBS) were withdrawn,
and the total release medium was replaced with
20 ml of fresh PBS to maintain the sink conditions.
The quantification of released drug was determined
by reverse-phase high performance liquid chro-
matography (RP-HPLC) using a Capcell-pack C18
column. The mobile phase for orlistat was
acetonitrile/water (95/5, v/v) with 0.1 % phosphoric
acid mobile phase over 15 minutes at a flow rate of
1.5 ml/ minute. The eluent was monitored by UV
absorption at 227 nm 11. In the case of caffeine, the
mobile phase was methanol/water (40/60, v/v)
mobile phase over 15 minutes at a flow rate of
0.5 ml/minute and the eluent was monitored by UV
absorption at 272 nm. In the case of ibuprofen,
the mobile phase was methanol/acetonitrile/water
(85/15/5, v/v) mobile phase over 15 minutes at a
flow rate of 1.0 ml/minute and the eluent was moni-
tored by UV absorption at 220 nm 12.
Statistical analysis
Data are expressed as the mean±S.E.M. of at
least three experiments. All data processing was
performed using the ORIGIN®8.0 statistical soft-
ware program (OriginLab Corp., Northampton,
MA, USA).
Results and discussion
Temperature-induced phase transition was
demonstrated in the melt state of Pluronic
F-68/Tween 80/soybean oil with model drugs to
perform the nanoencapsultion of drug-loaded lipid.
Liquid Tween 80/soybean oil was selected for
solubilizing drugs to form the drug-loaded lipid and
Pluronic F-68 was selected to encapsulate the
drug-loaded lipid on the nanometer scale. To decide
the proper temperature for transition, the transition
behavior of Pluronic F-68 and Pluronic F-68/Tween
80/soybean oil containing drug were performed,
which showed the melting transition around 53°C
and 50°C, respectively (see Figure 2).
According to Figure 2, the mixture composed
of Pluronic F-68/Tween 80/soybean oil containing
drug showed the melting transition at 50°C and the
formation of liquidized mixture was observed.
However, it took 2 hours to induce the formation of
the homogeneous solution mixture and increase of
melting temperature was required to set up for fast
and convenient process. Therefore, the melting
transition was performed at 75°C. The formation of
drug-loaded Pluronic NPs was induced when the
temperature was decreased to 0°C. The morphology
and size distribution of Pluronic NPs were exam-
ined by FE-SEM and particle size analyzer as
shown in Figure 3. Pluronic NPs had the spherical
form with approximately 220 nm in diameter. The
size distribution of drug-loaded Pluronic NPs does
not change significantly after 24-hour release ex-
periment. This indicates that the stability of
Pluronic NPs was maintained in the aqueous media
during the release experiment.
The crystalline structure of drug causes limited
solubility in the aqueous media 13. With the nano-
encapsulation of drug-loaded lipid, drug-loaded
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F i g . 2 – DSC thermograms
lipid was coated with hydrophilic Pluronic F-68
and this led to the improved stability of drug in the
aqueous media. As shown in Figure 3, the
nanoencapsulated drug-loaded lipids (Pluronic
NPs) maintained their nano-sized diameter indicat-
ing the improved stability of drug (or drug-loaded
lipid) in the aqueous media. To understand the rela-
tionship between the crystallinity and the dissolu-
tion behavior more in detail, X-ray diffraction anal-
ysis was used by observing the change of
crystallinity during the nanoencapsulation. In this
study, orlistat, caffeine and ibuprofen sodium salt
were used as model drugs. Because caffeine and
ibuprofen sodium salt are soluble in water (The sol-
ubilities of caffeine and ibuprofen sodium salt are
22 mg/ml and 100 mg/ml, respectively 14–15), X-ray
diffraction analysis was not required. Therefore,
X-ray diffraction analysis was performed with
orlistat.
Orlistat and Pluronic F-68 showed the charac-
teristic crystalline structures as shown in Figures 4
(a) and 4(b). With liquid Tween 80/soybean oil as a
solubilizer for orlistat, the crystalline structure from
orlistat was completely disappeared, indicating that
orlistat mixed homogeneously in Tween 80/soybean
as shown in Figure 4 (c). This led to suppressing
the crystallization of orlistat in the Pluronic NPs
with the increased stability in the aqueous media.
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F i g . 3 – (a) FE-SEM images of Pluronic NPs and (b) the
size distribution of Pluronic NPs after 24-hour re-
lease experiment
F i g . 4 – X-ray analysis for (a) free orlistat, (b) Pluronic
F-68, (c) melted mixture of orlistat/Tween 80/Soy-
bean oil/Pluronic F-68
Also, the increased solubility of orlistat in the
aqueous media was expected, as the amorphous
state of drug had higher penetration of water mole-
cules due to the disordered state of intermolecular
chains than the crystalline state 13, 16–17.
To optimize the composition of the Pluronic
NPs, the size change of the Pluronic NPs with
orlistat-loaded lipid cores were observed in PBS
with a variation of Tween 80/soybean oil ratio (see
Figure 5). The weight ratio of solubilizer (Tween
80/soybean oil mixture) and Pluronic was main-
tained 1:1 in this experiment. With the increase of
Tween 80, the size of Pluronic NPs was decreased
and the minimum size was obtained at the ratio of
1.0. The size change of Pluronic NPs was also ob-
served as a function of Pluronic content in the NPs
with maintaining the ratio of Tween 80/soybean oil
at 1. The size change of NPs was minimal with the
variation of Pluronic content in the NPs irrespective
of model drugs as shown in Figure 6.
Figure 7 shows the drug release patterns of
model drugs. Drug solubility played an important
role in determining the drug release pattern. In the
case of model drugs with high solubility such as
caffeine (the solubility: 22 mg/ml) and ibuprofen
salt (the solubility: 100 mg/ml), the released amount
was significantly high comparing with that of
orilistat (the solubility: practically insoluble18).
However, the sustained release pattern was demon-
strated indicating that Pluronic controls the release
of drugs from the Pluronic NPs. In the case of
model drug with low solubility such as orlistat, the
released amount was quite low comparing with caf-
feine and ibuprofen salt. However, the Pluronic
NPs improved the stability of orlistat in the aqueous
media significantly and we could expect that
Pluronic NPs could be utilized to accomplish the
sustained release of drugs with low solubility for
long period of time.
In the conventional preparation of NPs or
microparticles based on the emulsification/solvent
evaporation technique19–20, methylene chloride,
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F i g . 5 – The size changes of Pluronic NPs as a function of
Tween 80/Soybean oil (w/w) ratio. (The total num-
ber of experiments is three.)
F i g . 6 – The size changes of Pluronic NPs as a function of
Pluronic content in the NPs
ethyl acetate, or the mixture of methylene chloride
and methanol (or acetone) were used to prepare for
the homogeneous organic mixtures composed of
polymer, drug and surfactant. Although the solvent
is evaporated during the preparation, special care
should be taken to remove the residual solvent
completely for the clinical application. By success-
ful demonstration of NPs formed by tempera-
ture-induced phase transition, a new preparation
method for drug-loaded NPs was proposed without
using organic solvents.
Conclusions
Temperature-induced phase transition was per-
formed in the melt state of polymer/lipid/drug mix-
ture and the nanoencapsulation was successfully
demonstrated to form nanocarriers for the drug de-
livery system. With the presence of polymer
(Pluronic F-68) around the drug-loaded lipid core,
the stability of model drug with low solubility was
improved in the aqueous media and the release pat-
tern of water-soluble drug was controlled. These
preliminary results indicate that temperature-in-
duced phase transition may be very useful process
for the preparation of a particle-type drug carrier
without using organic solvent.
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